PRDM1 expression and prognostic value in patients with diffuse large B-cell lymphoma

Yanyan LIU,Jingyi SHI,Jie MA,Yongping SONG,Weili ZHAO,Saijuan CHNE
DOI: https://doi.org/10.3969/j.issn.1004-437X.2008.01.005
2008-01-01
Abstract:Objective: To explore PRDM1 expression and prognostic value in patients with diffuse large B-cell lymphoma.Methods: 82 patients with diffuse large B-cell lymphoma(DLBCL) were divided into germinal center and non-germinal center subtypes according CD10,BCL6 and IRF4 expression with immunohistichemistry(IHC).Laser microdissectin combined with reverse transcription-polymerase chain reaction(RT-PCR) and Western blot were used to detect PRDM1 expressionin two subtypes of DLBCL patients.Results: Correlation of PRDM1 expression with survival was analyzed by SAS software in CHOP and rituximab combined with CHOP(R-CHOP) treatment.We observed PRDM1 expression in Namalwa cell line and its alteration after being treated by rituximab,doxorubicin and rituximab plus doxorubicin with semiquantitative RT-PCR and Western blot.Enzyme-linked immunosobent assay(ELISA) was applied to assess the relation between PRDM1 and nuclear factor(NF)-kappa B activity.It was significant when P value was less than 0.05.Results: There exists PRDM1α and β isoforms which dorminantly expressed in lymphoma cells of non-germinal center subtype(73.5% vs 38.8%,39.4% vs6.1%;P=0.0020 and P=0.0009),moreover,PRDM1β predicted shorter survival in CHOP treatment,not in R-CHOP.PRDM1β also expressed in Namalwa cell line and could be downregulated after treating with rituximab and rituximab plus doxorubicin,accompanying to NF-kB inactivity.Conclusion: PRDM1 dorminantly expresses in lymphoma cells of non-germinal center subtype and PRDM1β may indicate poor prognosis in DLBCL patients.
What problem does this paper attempt to address?